Searching the genome for new genetic markers, associations, and combinations related to disease, using an AI assisted simulation model.

The original computer model (Fall 2021 NES 66,9 B01.00003, March 2023 APS JJ05.00007) has been enhanced with AI extensions and modified to generalize the insights gained in our studies of Type 1 Diabetes. Variations and mutations that appear benign or at least safe at the initial site may trigger disease in molecular pathways downstream as biosynthesis proceeds. The case of preproinsulin mRNA is a good example. Failure of a variant start codon to properly initiate the reading frame at the primary location for the translation, leads to simulation model predictions of translocation defects that cause the demise of the host beta cell. We see distant peptide events and behaviors contributing to conditions and illness related to genome patterns that are not immediately obvious in the DNA.



Our new system is named GPScanner and will be focused on diseases that have been steadily rising to include younger generations. Emphasis will be on prevention or early detection of Type 1 or 2 diabetes, unexplained breast cancer, and ovarian cancer. A new system has been announced by Google for its AI firm DeepMind. It will create opportunities for researchers to improve treatment outcomes across the genomic spectrum. Basic information and evaluations will be available to support new and innovative investigations. We expect our GPScanner to add value and to partner in this environment.